Tumour-Derived, Extracellular Microvesicles in the Treatment of Acute Renal Failure: An Experimental Study.

Q1 Medicine

Medical sciences (Basel, Switzerland) Pub Date : 2025-04-01 DOI:10.3390/medsci13020035

Galina V Seledtsova, Victor I Seledtsov, Ayana B Dorzhieva, Irina P Ivanova, Tatiana S Khabalova, Adas Darinskas, Alexei A von Delwig

{"title":"Tumour-Derived, Extracellular Microvesicles in the Treatment of Acute Renal Failure: An Experimental Study.","authors":"Galina V Seledtsova, Victor I Seledtsov, Ayana B Dorzhieva, Irina P Ivanova, Tatiana S Khabalova, Adas Darinskas, Alexei A von Delwig","doi":"10.3390/medsci13020035","DOIUrl":null,"url":null,"abstract":"Background/Objectives: This investigation compared the therapeutic efficacy of extracellular microvesicles (MVs) derived from murine L929 sarcoma cells and murine mesenchymal stem cells (MSCs). Methods: A mouse model of acute kidney injury (AKI) was used. Results: Both MVs from L929 cells (L929-MVs) and MSCs (MSC-MVs), unlike those obtained from murine peripheral blood mononuclear cells (PBMCs), enhanced survival rates in AKI mice and significantly improved kidney function. This was indicated by decreased levels of urine albumin and serum creatinine. Furthermore, treatment with L929-MVs and MSC-MVs elevated the proportions of CD4+CD25+FOXP3+ regulatory T cells while reducing the presence of pro-inflammatory CD4+CD44+ T cells in the spleens of AKI mice. Conclusions: the results highlight the potential of tumour-derived MVs to facilitate organ repair and exert cytoprotective immunomodulatory effects.","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"13 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12015901/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical sciences (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/medsci13020035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background/Objectives: This investigation compared the therapeutic efficacy of extracellular microvesicles (MVs) derived from murine L929 sarcoma cells and murine mesenchymal stem cells (MSCs). Methods: A mouse model of acute kidney injury (AKI) was used. Results: Both MVs from L929 cells (L929-MVs) and MSCs (MSC-MVs), unlike those obtained from murine peripheral blood mononuclear cells (PBMCs), enhanced survival rates in AKI mice and significantly improved kidney function. This was indicated by decreased levels of urine albumin and serum creatinine. Furthermore, treatment with L929-MVs and MSC-MVs elevated the proportions of CD4+CD25+FOXP3+ regulatory T cells while reducing the presence of pro-inflammatory CD4+CD44+ T cells in the spleens of AKI mice. Conclusions: the results highlight the potential of tumour-derived MVs to facilitate organ repair and exert cytoprotective immunomodulatory effects.

查看原文本刊更多论文

肿瘤来源的细胞外微泡治疗急性肾衰竭的实验研究。

背景/目的：本研究比较了小鼠L929肉瘤细胞和小鼠间充质干细胞（MSCs）的细胞外微泡（MVs）的治疗效果。方法：建立小鼠急性肾损伤（AKI）模型。结果：来自L929细胞（L929- mv）和MSCs （msc - mv）的mv与来自小鼠外周血单个核细胞（PBMCs）的mv不同，都能提高AKI小鼠的存活率，并显著改善肾功能。尿白蛋白和血清肌酐水平降低表明了这一点。此外，L929-MVs和MSC-MVs可提高AKI小鼠脾脏中CD4+CD25+FOXP3+调节性T细胞的比例，同时减少促炎CD4+CD44+ T细胞的存在。结论：肿瘤源性mv具有促进器官修复和发挥细胞保护性免疫调节作用的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊